Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT.

BACKGROUND: Bone marrow toxicity in advanced prostate cancer patients who receive [177Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [177Lu]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference. METHODS: Eight mHSPC patients underwent two cycles (3 and 6 GBq) of [177Lu]Lu-PSMA-617 therapy. After each cycle, five time point (1 h, 1 day, 2 days, 3 days, 7 days) SPECT/CT was performed at kidney level. Bone marrow dosimetry was performed using commercial software by drawing ten 1.5 cm diameter spheres in the lowest ten vertebrae to determine the time-integrated activity. Simplified protocols using only 2 imaging time points and 3 vertebrae were also compared. Blood-based dosimetry was based on the blood sampling method according to the EANM guideline. RESULTS: Mean bone marrow absorbed dose was significantly different (p < 0.01) for the imaging based method (25.4 ± 8.7 mGy/GBq) and the blood based method (17.2 ± 3.4 mGy/GBq), with an increasing absorbed dose ratio between both methods over time. Bland Altman analysis of both simplification steps showed that differences in absorbed dose were all within the 95% limits of agreement. CONCLUSION: This study showed that bone marrow absorbed dose after [177Lu]Lu-PSMA-617 can be determined using an imaging-based method of the lower vertebrae, and simplified using 2 time points (1 and 7 days) and 3 vertebrae. An increasing absorbed dose ratio over time between the imaging-based method and blood-based method suggests that there might be specific bone marrow binding of [177Lu]Lu-PSMA-617.

Preliminary Evaluation of Automated Speech Recognition Apps for the Hearing Impaired and Deaf.

OBJECTIVE: Automated speech recognition (ASR) systems have become increasingly sophisticated, accurate, and deployable on many digital devices, including on a smartphone. This pilot study aims to examine the speech recognition performance of ASR apps using audiological speech tests. In addition, we compare ASR speech recognition performance to normal hearing and hearing impaired listeners and evaluate if standard clinical audiological tests are a meaningful and quick measure of the performance of ASR apps. METHODS: Four apps have been tested on a smartphone, respectively AVA, Earfy, Live Transcribe, and Speechy. The Dutch audiological speech tests performed were speech audiometry in quiet (Dutch CNC-test), Digits-in-Noise (DIN)-test with steady-state speech-shaped noise, sentences in quiet and in averaged long-term speech-shaped spectrum noise (Plomp-test). For comparison, the app's ability to transcribe a spoken dialogue (Dutch and English) was tested. RESULTS: All apps scored at least 50% phonemes correct on the Dutch CNC-test for a conversational speech intensity level (65 dB SPL) and achieved 90-100% phoneme recognition at higher intensity levels. On the DIN-test, AVA and Live Transcribe had the lowest (best) signal-to-noise ratio +8 dB. The lowest signal-to-noise measured with the Plomp-test was +8 to 9 dB for Earfy (Android) and Live Transcribe (Android). Overall, the word error rate for the dialogue in English (19-34%) was lower (better) than for the Dutch dialogue (25-66%). CONCLUSION: The performance of the apps was limited on audiological tests that provide little linguistic context or use low signal to noise levels. For Dutch audiological speech tests in quiet, ASR apps performed similarly to a person with a moderate hearing loss. In noise, the ASR apps performed more poorly than most profoundly deaf people using a hearing aid or cochlear implant. Adding new performance metrics including the semantic difference as a function of SNR and reverberation time could help to monitor and further improve ASR performance.

Pulmonary nodule enhancement in subtraction CT and dual-energy CT: A comparison study.

OBJECTIVE: To compare nodule enhancement on subtraction CT iodine maps to that on dual-energy CT iodine maps using CT datasets acquired simultaneously. METHODS: A previously-acquired set of lung subtraction and dual-energy CT maps consisting of thirty patients with 95 solid pulmonary nodules (≥4 mm diameter) was used. Nodules were annotated and segmented on CT angiography, and mean nodule enhancement in the iodine maps calculated. Three radiologists scored nodule visibility with both techniques on a 4-point scale. RESULTS: Mean nodule enhancement was higher (p < 0.001) at subtraction CT (34.9 ±â€¯12.9 HU) than at dual-energy CT (25.4 ±â€¯21.0 HU). Nodule enhancement at subtraction CT was judged more often to be "highly visible" for each observers (p < 0.001) with an area under the curve of 0.81. CONCLUSIONS: Subtraction CT is able to depict iodine enhancement in pulmonary nodules better than dual-energy CT.

Iodine Maps from Subtraction CT or Dual-Energy CT to Detect Pulmonary Emboli with CT Angiography: A Multiple-Observer Study.

Background Dual-energy CT iodine maps are used to detect pulmonary embolism (PE) with CT angiography but require dedicated hardware. Subtraction CT, a software-only solution, results in iodine maps with high contrast-to-noise ratios. Purpose To compare the use of subtraction CT versus dual-energy CT iodine maps to CT angiography for PE detection. Materials and Methods In this prospective study ( https://clinicaltrials.gov , NCT02890706), 274 participants suspected of having PE underwent precontrast CT followed by contrast material-enhanced dual-energy CT angiography between July 2016 and April 2017. Iodine maps from dual-energy CT were derived. Subtraction maps (contrast-enhanced CT minus precontrast CT) were calculated after motion correction. Truth was established by expert consensus. A total of 75 randomly selected participants with and without PE (1:1 ratio) were evaluated by three radiologists and six radiology residents (blinded to final diagnosis) for the presence of PE using three types of CT: CT angiography alone, dual-energy CT, and subtraction CT. The partial area under the receiver operating characteristic curve (AUC) for the clinically relevant specificity region (maximum partial AUC, 0.11) was compared by using multireader multicase variance. A P value less than or equal to .025 was considered indicative of a significant difference due to multiple comparisons. Results There were 35 men and 40 women in the reader study (mean age, 63 years ± 12 [standard deviation]). The pooled sensitivities were not different (P ≥ .31 among techniques) (95% confidence intervals [CIs]: 67%, 89% for CT angiography; 72%, 91% for dual-energy CT; 70%, 91% for subtraction CT). However, pooled specificity was higher for subtraction CT (95% CI: 100%, 100%) than for CT angiography (95% CI: 89%, 97%) or dual-energy CT (95% CI: 89%, 98%) (P < .001). Partial AUCs for the average observer improved equally when adding iodine maps (subtraction CT [0.093] vs CT angiography [0.088], P = .03; dual-energy CT [0.094] vs CT angiography, P = .01; dual-energy CT vs subtraction CT, P = .68). Average reading times were equivalent (range, 97-101 seconds; P ≥ .41) among techniques. Conclusion Subtraction CT iodine maps had greater specificity than CT angiography alone in pulmonary embolism detection. Subtraction CT had comparable diagnostic performance to that of dual-energy CT, without the need for dedicated hardware. © RSNA, 2019 Online supplemental material is available for this article.

Image Quality of Iodine Maps for Pulmonary Embolism: A Comparison of Subtraction CT and Dual-Energy CT.

OBJECTIVE. The objective of this study was to compare the image quality of iodine maps derived from subtraction CT and from dual-energy CT (DECT) in patients with suspected pulmonary embolism (PE). SUBJECTS AND METHODS. In this prospective study conducted between July 2016 and April 2017, consecutive patients with suspected PE underwent unenhanced CT at 100 kV and dual-energy pulmonary CT angiography at 100 and 140 kV on a dual-source scanner. The scanner was set to generate subtraction and DECT iodine maps at similar radiation doses. In 55 patients (30 women, 25 men; mean age ± SD, 63.4 ± 11.9 years old), various subjective image quality criteria including diagnostic acceptability were rated on a 5-point scale by four radiologists and a radiology resident. In 29 patients (17 women, 12 men; mean age, 62.4 ± 11.7 years old) with confirmed perfusion defects, the signal-difference-to-noise ratio (SDNR) between perfusion defects and adjacent normally perfused parenchyma was measured in corresponding ROIs on subtraction and DECT iodine maps. McNemar and Wilcoxon signed-rank tests were used for statistical comparisons. RESULTS. Diagnostic acceptability was rated excellent or good in a mean of 67% (range, 31-80%) of subtraction CT studies and 36% (5-69%) of DECT studies (p < 0.05 for four of the five radiologists), mainly because of fewer artifacts on subtraction CT. Mean SDNR was marginally higher for subtraction CT than for DECT (18.6 vs 17.1, p = 0.06) and was significantly higher in the upper lobes (21.8 vs 17.9, p < 0.05). CONCLUSION. Radiologist-judged image quality of pulmonary iodine maps was higher for subtraction CT than for DECT with similar to higher SDNR. Subtraction CT is a software-only solution, so it may be an attractive alternative to DECT for depicting perfusion defects.

Accuracy of registration algorithms in subtraction CT of the lungs: A digital phantom study.

PURPOSE: The purpose of this study was to assess, using an anthropomorphic digital phantom, the accuracy of algorithms in registering precontrast and contrast-enhanced computed tomography (CT) chest images for generation of iodine maps of the pulmonary parenchyma via temporal subtraction. MATERIALS AND METHODS: The XCAT phantom, with enhanced airway and pulmonary vessel structures, was used to simulate precontrast and contrast-enhanced chest images at various inspiration levels and added CT simulation for realistic system noise. Differences in diaphragm position were varied between 0 and 20 mm, with the maximum chosen to exceed the 95th percentile found in a dataset of 100 clinical subtraction CTs. In addition, the influence of whole body movement, degree of iodine enhancement, beam hardening artifacts, presence of nodules and perfusion defects in the pulmonary parenchyma, and variation in noise on the registration were also investigated. Registration was performed using three lung registration algorithms - a commercial (algorithm A) and a prototype (algorithm B) version from Canon Medical Systems and an algorithm from the MEVIS Fraunhofer institute (algorithm C). For each algorithm, we calculated the voxel-by-voxel difference between the true deformation and the algorithm-estimated deformation in the lungs. RESULTS: The median absolute residual error for all three algorithms was smaller than the voxel size (1.0 × 1.0 × 1.0 mm3 ) for up to an 8 mm diaphragm difference, which is the average difference in diaphragm levels found clinically, and increased with increasing difference in diaphragm position. At 20 mm diaphragm displacement, the median absolute residual error after registration was 0.85 mm (interquartile range, 0.51-1.47 mm) for algorithm A, 0.82 mm (0.50-1.40 mm) for algorithm B, and 0.91 mm (0.54-1.52 mm) for algorithm C. The largest errors were seen in the paracardiac regions and close to the diaphragm. The impact of all other evaluated conditions on the residual error varied, resulting in an increase in the median residual error lower than 0.1 mm for all algorithms, except in the case of whole body displacements for algorithm B, and with increased noise for algorithm C. CONCLUSION: Motion correction software can compensate for respiratory and cardiac motion with a median residual error below 1 mm, which was smaller than the voxel size, with small differences among the tested registration algorithms for different conditions. Perfusion defects above 50 mm will be visible with the commercially available subtraction CT software, even in poorly registered areas, where the median residual error in that area was 7.7 mm.

Imaging of pulmonary perfusion using subtraction CT angiography is feasible in clinical practice.

Subtraction computed tomography (SCT) is a technique that uses software-based motion correction between an unenhanced and an enhanced CT scan for obtaining the iodine distribution in the pulmonary parenchyma. This technique has been implemented in clinical practice for the evaluation of lung perfusion in CT pulmonary angiography (CTPA) in patients with suspicion of acute and chronic pulmonary embolism, with acceptable radiation dose. This paper discusses the technical principles, clinical interpretation, benefits and limitations of arterial subtraction CTPA. KEY POINTS: • SCT uses motion correction and image subtraction between an unenhanced and an enhanced CT scan to obtain iodine distribution in the pulmonary parenchyma. • SCT could have an added value in detection of pulmonary embolism. • SCT requires only software implementation, making it potentially more widely available for patient care than dual-energy CT.